-
Analyst Sees Eli Lilly Fairly Valued At $81 Per Share, Downgrades To Hold
Thursday, April 27, 2017 - 10:06am | 363Argus analyst Katelyn Bayone believes shares of Eli Lilly and Co (NYSE: LLY) are fairly valued at around $81, which prompted her to downgrade the stock from Buy to Hold. According to Bayone, shares are trading near their 52-week high and also at a superior valuation versus its peers. In fact, the...
-
Following Q3 Results, Here's Where Eli Lilly Investors' Focus Is Turning
Wednesday, October 26, 2016 - 1:16pm | 333A day after Eli Lilly and Co (NYSE: LLY) reported earnings and sales misses for the third quarter, Goldman Sachs reduced its revenue and EPS estimate by 1–3 percent for 2016–2025 based on the conservative expectations of Jardiance, Humalog and Portrazza. However, the firm thinks that...
-
BMO Analysts Say Merck's Fundamentals Don't Justify Its Valuations
Monday, July 18, 2016 - 12:02pm | 586BMO has downgraded Merck & Co., Inc. (NYSE: MRK) shares to Market Perform from Outperform on valuation. "The so called 'TINA' (there is no alternative) effect is not enough for us to remain bullish at these levels; the fundamentals have not improved to justify higher valuations. In fact, we are...
-
Bank Of America: New Eli Lilly Data Is 'Game-Changing'
Friday, September 18, 2015 - 1:36pm | 362Shares of Eli Lilly and Co (NYSE: LLY) surged on Thursday, touching a 52-week high of $89.52. The move higher followed the release of positive data during the EASD conference. Colin Bristow of Bank of America maintained a Buy rating on the stock with a price target boosted to $108 from a previous...